Royalty Pharma buys royalty interests from drug developers, universities, and research institutions, then collects a percentage of sales revenue from the underlying drugs. It owns royalties on 35+ approved drugs across oncology, neurology, and rare diseases — including Imbruvica, Tysabri, and Vertex's cystic fibrosis drugs — plus stakes in drugs still in development. Revenue comes entirely from royalty payments tied to how well those drugs sell commercially.
Employees100IPOJun 16, 2020SIC2833HQ110 East 59th Street, New York, NY, USA, 10022
to
Financials
Profitability
Metric
Current
Margins
Gross Margin
—
Operating Margin
62.4%
EBITDA Margin
67.7%
Net Margin
32.1%
OCF Margin
117.4%
FCF Margin
117.4%
Returns on Capital
ROE
12.4%
ROA
4.2%
ROIC
8.6%
ROCE
9.2%
ROC (Greenblatt)
0.0%
3Y ROIIC
19.5%
Consistency
Years Profitable / 10Y
9
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
36.49
Forward P/E
11.15
P/E ex-NRI
39.36
Shiller P/E (CAPE)
—
Cash Flow Multiples
P/FCF
12.11
P/OCF
12.11
P/Owner Earnings
—
FCF Yield
5.80%
Enterprise Value Multiples
EV / EBIT
35.94
EV / Forward EBIT
37.24
EV / EBITDA
35.84
EV / Forward EBITDA
37.24
EV / Revenue
24.25
EV / Forward Revenue
22.69
Asset / Sales
P/S
14.31
P/B
7.51
P/Tangible Book
8.68
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
1.55%
Forward Dividend Yield
1.61%
3Y Dividend Growth
5.0%
Payout Ratio
0.61
5Y Yield on Cost
3.68%
Buybacks & Dilution
3Y Buyback Ratio
1.10%
Combined
Shareholder Yield
−0.26%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
1.31
Gross Debt / EBITDA
5.22
Cash / Debt
0.19
Equity / Assets
0.35
Coverage
Interest Coverage
4.38
Short-Term Liquidity
Current Ratio
2.80
Quick Ratio
2.80
Cash Ratio
2.74
Composite Scores
Piotroski F-Score
5
Altman Z-Score
3.72
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-08-14
$0.235
2026-09-10
2026-05-15
$0.235
2026-06-10
2026-02-20
$0.235
2026-03-10
2025-11-14
$0.22
2025-12-10
2025-08-15
$0.22
2025-09-10
2025-05-16
$0.22
2025-06-10
2025-02-21
$0.22
2025-03-10
2024-11-15
$0.21
2024-12-10
2024-08-16
$0.21
2024-09-13
2024-05-16
$0.21
2024-06-14
10 of 25
View allDate
Transcript
Type
2026-08-05
Q2 2026 Royalty Pharma PLC Earnings Call Transcript
Earnings Call
2026-06-09
Royalty Pharma PLC at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-05-19
Royalty Pharma PLC at RBC Capital Markets Global Healthcare Conference Transcript
Conference Presentations
2026-05-13
Royalty Pharma PLC at Bank of America Global Healthcare Conference Transcript
Conference Presentations
2026-05-06
Q1 2026 Royalty Pharma PLC Earnings Call Transcript
Earnings Call
2026-03-03
Royalty Pharma PLC at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-02-11
Q4 2025 Royalty Pharma PLC Earnings Call Transcript
Earnings Call
2026-01-13
Royalty Pharma PLC at JPMorgan Healthcare Conference Transcript
Conference Presentations
2025-12-03
Royalty Pharma PLC at Evercore ISI Healthcare Conference Transcript
Conference Presentations
2025-12-02
Royalty Pharma PLC at Citi Global Healthcare Conference Transcript
Conference Presentations
10 of 65
5-Step DuPont Analysis
ROE %
12.37%
×
×
Net Margin %
32.14%
×
×
Operating Margin %
62.34%
Operating Income
$1.58B
÷
Revenue
$2.54B
×
Tax Burden
0.6037
Net Income
$815M
÷
Pretax Income
$1.35B
×
Interest Burden
0.8539
Pretax Income
$1.35B
÷
Operating Income
$1.58B
×
Asset Turnover
0.13
÷
Revenue
$2.54B
÷
Average Total Assets
$19.07B
Begin Total Assets
$18.32B
End Total Assets
$19.82B
×
Equity Multiplier
2.89
÷
Avg Total Assets
$19.07B
÷
Avg Stockholders Equity
$6.59B
Begin Equity
$6.35B
End Equity
$6.83B
Top institutional holders
Q2 2026| Holder | Shares | Chg. shares | |
|---|---|---|---|
| MORGAN STANLEY | 42.9M | -640.0K | $2.41B |
| Capital International Investors | 35.3M | +268.0K | $1.98B |
| BlackRock, Inc. | 27.8M | +1.9M | $1.56B |
| FMR LLC | 24.5M | -638.4K | $1.37B |
| STATE STREET CORP | 12.3M | +1.3M | $691.80M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 11.2M | +9.3M | — |
| Swedbank AB | 10.7M | -860.1K | $601.44M |
| BAILLIE GIFFORD & CO | 10.0M | -6.1M | $561.57M |
| Capital World Investors | 9.5M | +1.5M | $533.64M |
| GEODE CAPITAL MANAGEMENT, LLC | 8.1M | +188.4K | $450.58M |
10 of 653
View allTop insider holdings
as reported| Insider | Shares held | |
|---|---|---|
| Hite ChristopherOfficer | 293.6K | $17.90M |
| Norden GregoryDirector | 196.3K | $11.97M |
| Fernandez Henry ADirector | 123.5K | $7.53M |
| DESOUZA ERROL BDirector | 81.4K | $4.96M |
| Bassler Bonnie LDirector | 79.8K | $4.87M |
| LOVE TED WDirector | 58.4K | $3.56M |
| Engelbert Catherine M.Director | 55.7K | $3.39M |
| Legorreta Pablo G.Officer | — | — |
| Coyne Terrance P.Officer | — | — |
| Lloyd George W.Officer | — | — |
10 of 15· 3 withheld
View allRecent insider activity
through Oct 5, 2026| Insider | Action | Shares | Date | |
|---|---|---|---|---|
| Urist MarshallOfficer | Open-Market or Private Sale | -4.1K | $235.6K | Oct 5, 2026 |
| Bassler Bonnie LDirector | Grant/Award (Rule 16b-3(d)) | +642 | $37.5K | Sep 30, 2026 |
| Urist MarshallOfficer | Open-Market or Private Sale | -4.1K | $238.8K | Sep 28, 2026 |
| Hite ChristopherOfficer | Open-Market or Private Sale | -96.1K | $5.62M | Sep 22, 2026 |
| Hite ChristopherOfficer | Open-Market or Private Sale | -3.9K | $231.4K | Sep 22, 2026 |
| Hite ChristopherOfficer | Gift | -16.8K | $0 | Aug 19, 2026 |
| Hite ChristopherOfficer | Open-Market or Private Sale | -100.0K | $6.00M | Aug 18, 2026 |
| Coyne Terrance P.Officer | Open-Market or Private Sale | -9.2K | $540.8K | Aug 13, 2026 |
| Coyne Terrance P.Officer | Open-Market or Private Sale | -1.8K | $104.8K | Aug 13, 2026 |
| Urist MarshallOfficer | Grant/Award (Rule 16b-3(d)) | +8.3K | $0 | Aug 5, 2026 |
10 of 483
View all